Lionnet et al. 1 recently reported a high prevalence of retinopathy (RET) and otologic disorders (OTD) in patients with sickle cell-hemoglobin C disease (SC), while a significant number of patients had renal diseases (mainly glomerulopathy; GLO) and osteonecrosis (OST). The pathophysiological processes of these complications in SC are not well defined, although blood hyperviscosity has been suspected, but never tested to the best of our knowledge, as responsible for several chronic complications in SC disease 1, 2 . The aim of this study was to analyze the associations between hematological and hemorheological parameters and chronic complications in adult SC patients.
Ninety consecutive adults with SC (M/F: 40/50; mean age: 38 ± 13 yr) were enrolled in the study. All patients were at steady state at study entry, i.e., no phlebotomy or blood transfusions in the previous three months, and absence of acute episodes (infection, vasoocclusive crisis (VOC), acute chest syndrome (ACS), stroke, priapism) at least three months before enrollment. Pregnancy or breast feeding were also exclusion criteria. The study was conducted in accordance to the Declaration of Helsinki, and approved by the Regional Ethics Committee (registration number: 2010-A00244-35). Written informed consent was obtained from all participants.
History, presence of chronic disorders, and acute event occurrence during the previous year of study were obtained from retrospective chart review by two physicians. Patients under regular phlebotomy protocols, but without any phlebotomy in the 3 months preceding the study were identified. Phlebotomy is usually performed in symptomatic SC patients to avoid recurrent acute events
and has been prescribed by some when hemoglobin and/or hematocrit rise above 11 g/dL or 32%, respectively, to prevent complications with suspected blood hyperviscosity 1 , 4 . The optimal target hemoglobin level to reach under phlebotomy is unknown but our Sickle Cell Centre usually tries to reduce hemoglobin to 9.5-10.5 g/dL. In our study, SC patients with values greater than 11 g/dL and 32% but no clinical assessment of blood viscosity were categorized as having "theoretical hyperviscosity".
Measurements of hematological and hemolytic parameters (bilirubin, lactate dehydrogenase, aspartate aminotransferase) were performed using standard methods
.
Blood viscosity, red blood cell (RBC) deformability, aggregation and disaggregation threshold (i.e., RBC aggregates strength) were measured as described The most prevalent chronic complications in our SC cohort were RET (60%), GLO (micro-/macro-albuminuria, 40%), OST (31%), and OTD (20%). Leg ulcers, pulmonary hypertension and cerebral vasculopathy/stroke were extremely rare (2% each), as were ACS (2%) and VOC (5%) during the study period. Few males (8%) had a history of priapism.
Patients with OTD (OTD+) had higher RBC count (p<0.05), and a tendency to higher hemoglobin level than patients without OTD (OTD-; p<0.1; This is in agreement with our cohort where OTD+ patients had higher blood viscosity than OTD-. However, OTD+ had only a trend towards higher hemoglobin and similar hematocrit as OTD-. Blood viscosity is influenced by several factors, including hematocrit and hemoglobin, hence their clinical use to prescribe phlebotomy.
However, this relationship was not significant in our cohort. Blood viscosity depends also on the rheological properties of RBCs: i.e., deformability and aggregation. For a given hemoglobin level, increased RBC deformability lowers blood viscosity while increased RBC aggregation causes a rise. The complex contribution of each hemorheological factor on blood viscosity makes that blood viscosity may be elevated in some patients despite "normal" hematocrit and hemoglobin levels.
More importantly, most patients with "theoretical hyperviscosity" did not have high blood viscosity, and only 44% of patients with measured "true hyperviscosity" were phlebotomized.
Thus, as periodic phlebotomy could be useful to decrease blood viscosity in hyperviscous SC patients as it is in patients with polycythemia vera 10 or cyanotic congenital heart disease 11 , our findings strongly suggest that blood viscosity measurements would allow better identification of SC patients at risk for OTD.
In contrast to OTD, RET was not associated with blood hyperviscosity. Instead, RBC deformability was decreased by 10% in RET+ compared to RET-patients. RBC deformability is critical for optimal tissue perfusion and adequate blood flow in the micro-/ macro-circulation The effects of phlebotomy on RBC deformability in SC patients with RET have never been investigated, calling for further studies to address this question.
In conclusion, our study provides new data on the pathophysiology of several frequent chronic complications in SC disease. They clearly show that the clinical use of hemoglobin and hematocrit as surrogates for high blood viscosity in SC patients is not satisfactory for establishing treatment or determining risk for OTD. A prospective study to evaluate the relationships between blood rheology and the occurrence of acute complications is warranted. X.W. was supported by the association "Ensemble contre la drépanocytose" and by the regional council of Guadeloupe. We declare no conflict of interest. 
